BROS vs LAB · P/E 105, rev $1.28B vs rev $174.4M
Dutch Bros Inc (BROS) versus Standard Biotools Inc (LAB) — a side-by-side from cached financials, not a winner call.
Dutch Bros Inc (BROS) is a restaurants company listed on NYSE.
Standard Biotools Inc (LAB) is a medical devices company listed on NASDAQ.
Latest reported BROS revenue for 2024-12-31 was $1.28B. Net income was $66.5M. Revenue was up 32.6% from 2023-12-31 to 2024-12-31. BROS currently screens at market cap $11.74B and trailing P/E 105.0.
Latest reported LAB revenue for 2024-12-31 was $174.4M. Net income was -$138.9M. Revenue was up 64.0% from 2023-12-31 to 2024-12-31. LAB currently screens at market cap $317.1M.
BROS currently screens at market cap $11.74B and trailing P/E 105.0. LAB currently screens at market cap $317.1M.
Not investment advice. Open the BROS and LAB stock pages for the full models.
Not investment advice.